Published in Am J Physiol Heart Circ Physiol on January 27, 2012
Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin. Circulation (2015) 1.96
Membrane-associated matrix proteolysis and heart failure. Circ Res (2013) 1.35
Cellular mechanisms of tissue fibrosis. 2. Contributory pathways leading to myocardial fibrosis: moving beyond collagen expression. Am J Physiol Cell Physiol (2012) 1.21
Angiotensin II stimulates cardiac fibroblast migration via the differential regulation of matrixins and RECK. J Mol Cell Cardiol (2013) 0.98
Alcohol modulation of cardiac matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs favors collagen accumulation. Alcohol Clin Exp Res (2013) 0.91
Gender differences in non-ischemic myocardial remodeling: are they due to estrogen modulation of cardiac mast cells and/or membrane type 1 matrix metalloproteinase. Pflugers Arch (2013) 0.87
Substance P acting via the neurokinin-1 receptor regulates adverse myocardial remodeling in a rat model of hypertension. Int J Cardiol (2013) 0.84
Predictive utility of the changes in matrix metalloproteinase-2 in the early phase for left ventricular reverse remodeling after an acute myocardial infarction. J Am Heart Assoc (2015) 0.84
β3 integrin in cardiac fibroblast is critical for extracellular matrix accumulation during pressure overload hypertrophy in mouse. PLoS One (2012) 0.84
Targeted overexpression of tissue inhibitor of matrix metalloproteinase-4 modifies post-myocardial infarction remodeling in mice. Circ Res (2014) 0.83
Mechanistic relationship between membrane type-1 matrix metalloproteinase and the myocardial response to pressure overload. Circ Heart Fail (2014) 0.83
Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction: Data From the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction Study. Circ Heart Fail (2016) 0.81
HDACs Regulate miR-133a Expression in Pressure Overload-Induced Cardiac Fibrosis. Circ Heart Fail (2015) 0.79
Docosahexaenoic acid reverses angiotensin II-induced RECK suppression and cardiac fibroblast migration. Cell Signal (2014) 0.77
Atrial remodeling is directly related to end-diastolic left ventricular pressure in a mouse model of ventricular pressure overload. PLoS One (2013) 0.77
Cardiac-restricted overexpression or deletion of tissue inhibitor of matrix metalloproteinase-4: differential effects on left ventricular structure and function following pressure overload-induced hypertrophy. Am J Physiol Heart Circ Physiol (2014) 0.76
Mechanical Regulation of Cardiac Aging in Model Systems. Circ Res (2016) 0.76
Lactosylceramide contributes to mitochondrial dysfunction in diabetes. J Lipid Res (2016) 0.75
Exploring the biology of valvular heart disease: Time to move into the twenty-first century. Glob Cardiol Sci Pract (2013) 0.75
Differential membrane type 1 matrix metalloproteinase substrate processing with ischemia-reperfusion: relationship to interstitial microRNA dynamics and myocardial function. J Thorac Cardiovasc Surg (2012) 0.75
Non-human primate and rat cardiac fibroblasts show similar extracellular matrix-related and cellular adhesion gene responses to substance P. Heart Lung Circ (2014) 0.75
Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr (2005) 46.32
Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem (1995) 5.57
Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer (2002) 5.57
Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev (2007) 4.69
Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol (2005) 4.03
Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. Circulation (2007) 3.78
Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules. J Biol Chem (1997) 3.74
A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation (2000) 2.94
Impact of myocardial fibrosis in patients with symptomatic severe aortic stenosis. Circulation (2009) 2.88
Matrix metalloproteinases (MMPs) in health and disease: an overview. Front Biosci (2006) 2.81
Prognostic significance of myocardial fibrosis quantification by histopathology and magnetic resonance imaging in patients with severe aortic valve disease. J Am Coll Cardiol (2010) 2.38
Matrix metalloproteinases regulate migration, proliferation, and death of vascular smooth muscle cells by degrading matrix and non-matrix substrates. Cardiovasc Res (2005) 2.15
Cardiac support device modifies left ventricular geometry and myocardial structure after myocardial infarction. Circulation (2005) 2.14
Membrane protease proteomics: Isotope-coded affinity tag MS identification of undescribed MT1-matrix metalloproteinase substrates. Proc Natl Acad Sci U S A (2004) 1.91
Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart. Cardiovasc Res (2010) 1.90
Expression of matrix metalloproteinases during rat skin wound healing: evidence that membrane type-1 matrix metalloproteinase is a stromal activator of pro-gelatinase A. J Cell Biol (1997) 1.49
Effects of early and late chronic pressure overload on extracellular matrix remodeling. Hypertens Res (2008) 1.47
Pressure overload-induced alterations in fibrillar collagen content and myocardial diastolic function: role of secreted protein acidic and rich in cysteine (SPARC) in post-synthetic procollagen processing. Circulation (2008) 1.45
Degradomics: systems biology of the protease web. Pleiotropic roles of MMPs in cancer. Cancer Metastasis Rev (2006) 1.43
Age-dependent alterations in fibrillar collagen content and myocardial diastolic function: role of SPARC in post-synthetic procollagen processing. Am J Physiol Heart Circ Physiol (2009) 1.41
Diastolic relaxation and compliance reserve during dynamic exercise in heart failure with preserved ejection fraction. Heart (2011) 1.41
A unique substrate binding mode discriminates membrane type-1 matrix metalloproteinase from other matrix metalloproteinases. J Biol Chem (2002) 1.33
Multifunctional roles of MT1-MMP in myofiber formation and morphostatic maintenance of skeletal muscle. J Cell Sci (2006) 1.32
Matrix metalloproteinase-dependent activation of latent transforming growth factor-beta controls the conversion of osteoblasts into osteocytes by blocking osteoblast apoptosis. J Biol Chem (2002) 1.28
Membrane-type matrix metalloproteinase-1 (MT1-MMP) is a processing enzyme for human laminin gamma 2 chain. J Biol Chem (2004) 1.21
MT1-MMP is the critical determinant of matrix degradation and invasion by ovarian cancer cells. Br J Cancer (2007) 1.14
Trafficking of the membrane type-1 matrix metalloproteinase in ischemia and reperfusion: relation to interstitial membrane type-1 matrix metalloproteinase activity. Circulation (2005) 1.11
Cardiac restricted overexpression of membrane type-1 matrix metalloproteinase causes adverse myocardial remodeling following myocardial infarction. J Biol Chem (2010) 1.09
Effects of cyclic mechanical stretch on extracellular matrix synthesis by human scleral fibroblasts. Exp Eye Res (2006) 1.08
Paradoxical effects of a synthetic metalloproteinase inhibitor that blocks both p55 and p75 TNF receptor shedding and TNF alpha processing in RA synovial membrane cell cultures. J Clin Invest (1996) 1.05
Differential effects of mechanical and biological stimuli on matrix metalloproteinase promoter activation in the thoracic aorta. Circulation (2009) 1.03
Substrate choice of membrane-type 1 matrix metalloproteinase is dictated by tissue inhibitor of metalloproteinase-2 levels. Cancer Sci (2007) 1.01
Membrane-type-1 matrix metalloproteinase transcription and translation in myocardial fibroblasts from patients with normal left ventricular function and from patients with cardiomyopathy. Am J Physiol Cell Physiol (2007) 1.00
Cardiac-restricted overexpression of membrane type-1 matrix metalloproteinase in mice: effects on myocardial remodeling with aging. Circ Heart Fail (2009) 0.97
Myocardial remodeling: cellular and extracellular events and targets. Annu Rev Physiol (2011) 0.97
Type I collagen-induced MMP-2 activation coincides with up-regulation of membrane type 1-matrix metalloproteinase and TIMP-2 in cardiac fibroblasts. J Biol Chem (2003) 0.96
Proteolytic activation of heparin-binding EGF-like growth factor by membrane-type matrix metalloproteinase-1 in ovarian carcinoma cells. Cancer Sci (2010) 0.92
Phagocytosis of collagen by fibroblasts and invasive cancer cells is mediated by MT1-MMP. Biochem Soc Trans (2007) 0.88
Alterations in membrane type-1 matrix metalloproteinase abundance after the induction of thoracic aortic aneurysm in a murine model. Am J Physiol Heart Circ Physiol (2010) 0.86
Heterogeneity in MT1-MMP activity with ischemia-reperfusion and previous myocardial infarction: relation to regional myocardial function. Am J Physiol Heart Circ Physiol (2010) 0.84
Cyclic strain stimulates early growth response gene product 1-mediated expression of membrane type 1 matrix metalloproteinase in endothelium. Lab Invest (2002) 0.84
Differential effects of shear stress and cyclic strain on Sp1 phosphorylation by protein kinase Czeta modulates membrane type 1-matrix metalloproteinase in endothelial cells. Endothelium (2008) 0.83
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med (2004) 23.44
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med (2013) 16.33
Diastolic heart failure--abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med (2004) 8.12
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood (2013) 4.17
Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst (2006) 3.63
Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation (2011) 3.48
Systolic and diastolic mechanics in stress cardiomyopathy. Circulation (2014) 3.36
Large animal models of heart failure: a critical link in the translation of basic science to clinical practice. Circ Heart Fail (2009) 2.72
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med (2015) 2.66
Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J Clin Oncol (2009) 2.34
Animal models of heart failure: a scientific statement from the American Heart Association. Circ Res (2012) 2.31
Matrix metalloproteinase-9 gene deletion facilitates angiogenesis after myocardial infarction. Am J Physiol Heart Circ Physiol (2005) 2.23
Cardiac support device modifies left ventricular geometry and myocardial structure after myocardial infarction. Circulation (2005) 2.14
Region- and type-specific induction of matrix metalloproteinases in post-myocardial infarction remodeling. Circulation (2003) 1.95
Myocardial infarct expansion and matrix metalloproteinase inhibition. Circulation (2003) 1.91
Aortic dilatation with bicuspid aortic valves: cusp fusion correlates to matrix metalloproteinases and inhibitors. Ann Thorac Surg (2011) 1.88
Noninvasive targeted imaging of matrix metalloproteinase activation in a murine model of postinfarction remodeling. Circulation (2005) 1.82
Targeted myocardial microinjections of a biocomposite material reduces infarct expansion in pigs. Ann Thorac Surg (2008) 1.82
Preoperative statin treatment is associated with reduced postoperative mortality and morbidity in patients undergoing cardiac surgery: an 8-year retrospective cohort study. J Thorac Cardiovasc Surg (2006) 1.78
Mitral regurgitation augments post-myocardial infarction remodeling failure of hypertrophic compensation. J Am Coll Cardiol (2008) 1.70
Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: relation to left ventricular remodeling. Circulation (2006) 1.69
Complete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival. Cancer (2014) 1.68
Age-dependent changes in myocardial matrix metalloproteinase/tissue inhibitor of metalloproteinase profiles and fibroblast function. Cardiovasc Res (2004) 1.68
Angiotensin II receptor blockade does not improve left ventricular function and remodeling in subacute mitral regurgitation in the dog. J Am Coll Cardiol (2002) 1.65
Cardioprotective and antiapoptotic effects of heme oxygenase-1 in the failing heart. Circulation (2010) 1.64
Aprotinin in cardiac surgery: a review of conventional and novel mechanisms of action. Anesth Analg (2007) 1.57
Microtubule-dependent distribution of mRNA in adult cardiocytes. Am J Physiol Heart Circ Physiol (2008) 1.55
Plasma biomarkers for distinguishing etiologic subtypes of thoracic aortic aneurysm disease. J Thorac Cardiovasc Surg (2013) 1.54
Lymphocyte cytosolic protein 1 is a chronic lymphocytic leukemia membrane-associated antigen critical to niche homing. Blood (2013) 1.50
Standardized preoperative corticosteroid treatment in neonates undergoing cardiac surgery: results from a randomized trial. J Thorac Cardiovasc Surg (2011) 1.50
Accelerated LV remodeling after myocardial infarction in TIMP-1-deficient mice: effects of exogenous MMP inhibition. Am J Physiol Heart Circ Physiol (2005) 1.47
A prospective, randomized study of endothelin and postoperative recovery in off-pump versus conventional coronary artery bypass surgery. J Cardiothorac Vasc Anesth (2004) 1.46
Matrix metalloproteinase-7 affects connexin-43 levels, electrical conduction, and survival after myocardial infarction. Circulation (2006) 1.46
Deficiency of TIMP-1 exacerbates LV remodeling after myocardial infarction in mice. Am J Physiol Heart Circ Physiol (2002) 1.45
Pressure overload-induced alterations in fibrillar collagen content and myocardial diastolic function: role of secreted protein acidic and rich in cysteine (SPARC) in post-synthetic procollagen processing. Circulation (2008) 1.45
FAST at MACH 20: clinical ultrasound aboard the International Space Station. J Trauma (2005) 1.44
Selective spatiotemporal induction of matrix metalloproteinase-2 and matrix metalloproteinase-9 transcription after myocardial infarction. Am J Physiol Heart Circ Physiol (2006) 1.43
Expression of matrix metalloproteinases and endogenous inhibitors within ascending aortic aneurysms of patients with bicuspid or tricuspid aortic valves. J Thorac Cardiovasc Surg (2007) 1.42
Matrix metalloproteinase abundance in human myocardial fibroblasts: effects of sustained pharmacologic matrix metalloproteinase inhibition. J Mol Cell Cardiol (2003) 1.42
Transforming growth factor-beta signaling in thoracic aortic aneurysm development: a paradox in pathogenesis. J Vasc Res (2008) 1.42
Extracellular matrix remodeling following myocardial injury. Ann Med (2003) 1.41
Age-dependent alterations in fibrillar collagen content and myocardial diastolic function: role of SPARC in post-synthetic procollagen processing. Am J Physiol Heart Circ Physiol (2009) 1.41
Selective targeting and timing of matrix metalloproteinase inhibition in post-myocardial infarction remodeling. Circulation (2003) 1.40
Modulation of calcium transport improves myocardial contractility and enzyme profiles after prolonged ischemia-reperfusion. Ann Thorac Surg (2003) 1.39
Expression of matrix metalloproteinases and endogenous inhibitors within ascending aortic aneurysms of patients with Marfan syndrome. Circulation (2006) 1.32
Proteinase systems and thoracic aortic aneurysm progression. J Surg Res (2007) 1.32
Pathways of matrix metalloproteinase induction in heart failure: bioactive molecules and transcriptional regulation. Cardiovasc Res (2006) 1.29
ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol. Blood (2012) 1.27
Cardiac extracellular matrix remodeling: fibrillar collagens and Secreted Protein Acidic and Rich in Cysteine (SPARC). J Mol Cell Cardiol (2009) 1.27
Ceramide synthase 5 mediates lipid-induced autophagy and hypertrophy in cardiomyocytes. J Clin Invest (2012) 1.25
Early postoperative outcomes and blood product utilization in adult cardiac surgery: the post-aprotinin era. Circulation (2011) 1.24
Positively charged ceramide is a potent inducer of mitochondrial permeabilization. J Biol Chem (2005) 1.23
Mesenchymal cell transplantation and myocardial remodeling after myocardial infarction. Circulation (2009) 1.23
Regional heterogeneity within the aorta: relevance to aneurysm disease. J Thorac Cardiovasc Surg (2008) 1.23
Tumor necrosis factor-alpha and myocardial remodeling in progression of heart failure: a current perspective. Cardiovasc Res (2002) 1.21
Cellular mechanisms of tissue fibrosis. 2. Contributory pathways leading to myocardial fibrosis: moving beyond collagen expression. Am J Physiol Cell Physiol (2012) 1.21
Selective microRNA suppression in human thoracic aneurysms: relationship of miR-29a to aortic size and proteolytic induction. Circ Cardiovasc Genet (2011) 1.20
Early repair of moderate ischemic mitral regurgitation reverses left ventricular remodeling: a functional and molecular study. Circulation (2007) 1.20
Myosin light chain phosphorylation is critical for adaptation to cardiac stress. Circulation (2012) 1.19
Plasma biomarkers that reflect determinants of matrix composition identify the presence of left ventricular hypertrophy and diastolic heart failure. Circ Heart Fail (2011) 1.19
Beta3 integrin-mediated ubiquitination activates survival signaling during myocardial hypertrophy. FASEB J (2009) 1.19
TNF-alpha and myocardial matrix metalloproteinases in heart failure: relationship to LV remodeling. Am J Physiol Heart Circ Physiol (2002) 1.17
Left ventricular form and function: scientific priorities and strategic planning for development of new views of disease. Circulation (2004) 1.16
Effects of age on plasma matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs). J Card Fail (2007) 1.16
A murine model of thoracic aortic aneurysms. J Surg Res (2003) 1.16
Biomarkers of diastolic dysfunction and myocardial fibrosis: application to heart failure with a preserved ejection fraction. J Cardiovasc Transl Res (2013) 1.15
Effects of deletion of the matrix metalloproteinase 9 gene on development of murine thoracic aortic aneurysms. Circulation (2005) 1.15